On March 10, 2021 BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercializing innovative medicines worldwide, reported multiple presentations at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting 2021, including three oral presentations to highlight clinical data on anti-PD-1 antibody tislelizumab and on investigational spectrum-selective kinase inhibitor sitravatinib in combination with tislelizumab, and one poster presentation of preclinical data on its investigational anti-TIGIT antibody ociperlimab (BGB-A1217) (Press release, BeiGene, MAR 10, 2021, View Source [SID1234576427]). The AACR (Free AACR Whitepaper) Annual Meeting will take place in a virtual format on April 10-15 and May 17-21, 2021.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Oral Presentations:
Title:
Results from RATIONALE 303: A global Phase 3 study of tislelizumab versus docetaxel as second or third-line therapy for patients with locally advanced or metastatic NSCLC
Presentation #:
CT039
Session Title:
Disease-Oriented Innovative Clinical Research and Trials
Date and Time:
Monday, April 12, 2021 at 1:30 – 3:15 p.m. ET
Presenter:
Professor Caicun Zhou, Shanghai Pulmonary Hospital, China
Title:
Safety/tolerability and preliminary antitumor activity of sitravatinib plus tislelizumab in patients with advanced platinum-resistant ovarian cancer (PROC)
Presentation #:
CT013
Session Title:
Targeted Therapy and Ovarian Cancer Trials
Date and Time:
Sunday, April 11, 2021 at 2:00 – 3:45 p.m. ET
Presenter:
Jeffrey Goh, MBBS, FRACP, Icon Cancer Centre, Australia
Title:
Safety/tolerability and preliminary antitumor activity of sitravatinib plus tislelizumab in patients with PD-(L)1 refractory/resistant unresectable or metastatic melanoma from a phase 1b study
Presentation #:
CT035
Session Title:
Clinical Trials with Novel Immuno-Oncology Strategies
Date and Time:
Sunday, April 11, 2021 at 4:00 – 5:45 p.m. ET
Presenter:
Professor Chuanliang Cui, Beijing Cancer Hospital, China